LSP launches €150m fund dedicated to dementia treatment

The fund will be managed by Philip Scheltens, a neurologist and professor of cognitive neurology at Amsterdam University Medical Centers, who also heads the Alzheimer Center Amsterdam.

"Venture capital has proven to play an essential role in advancing biotech companies, but dementia opportunities remained largely unfunded," said LPS managing partner René Kuijten. "Together with Philip and his network, we now have a truly unique expertise in-house to identify and develop breakthrough ideas in the dementia field, ultimately leading to solutions for patients suffering from this terrible disease."

With offices in Amsterdam, Munich and Boston, LSP is currently managing three funds, in addition to this new vehcle, each with a distinctive investment scope and a dedicated team: LSP 6 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies with a health and economic benefit; and LSP Public targets public healthcare companies.

Among LSP's noticeable deals are Argenx, Crucell, KuDOS, Movetis, Neuravi, Okairos, Prosensa, Qiagen and Zealand Pharma. 

Investors
In just a few months on the road, LSP raised €50m from strategic parties, financial institutions and family offices. LSP believes that the fund will ultimately reach at least €150m, given this significant appetite among investors, the firm said in a statement.

Investments
The vehicle will invest in companies that are developing drugs for neurodegenerative diseases, focusing on all stages of dementia drugs, medtech development and novel treatments.

People
LSP – René Kuijten (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Funds
• Venture
• Benelux
• France
• DACH
• UK / Ireland
• Southern Europe
• Nordics
• CEE
• Venture